智通财经APP讯，诺诚健华(09969)公布2026年中期业绩，收益约11.37亿元，同比增长55.46%;经调整利润约2.77亿元，同比扭亏为盈;母公司拥有人应占溢利约2.46亿元，同比扭亏为盈。
公告称，收益增长主要是由于药物销售收益的强劲增长，以及与Zenas BioPharma, Inc.(纳斯达克代码： ZBIO)合作所产生的里程碑交付成果。药物销售由截至2025年6月30日止六个月的6.41亿元增加43.2%至9.18亿元，主要是由于奥布替尼持续的强劲增长以及坦昔妥单抗和佐来曲替尼的新上市。
于报告期内，诺诚健华进一步推进其多产品、多领域的战略，在血液肿瘤、自身免疫性疾病及实体瘤领域的贡献持续扩大。多项资产迈向或已达成关键监管与临床里程碑，为持续长期增长奠定坚实基础。
随着多项产品商业化或即将提交监管申请，诺诚健华已迈入多元化增长的新阶段，不仅提升了盈利可预测性，更扩大全球业务布局。凭借严谨的执行力及产品组合扩展，公司具备可持续创造价值的充分优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.